Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer

Inclusion Criteria: * Reads, understands and is able and willing to sign informed consent form * Males greater than or equal to age 45 * Histologically and cytologically documented prostate carcinoma * Candidate for initial hormone therapy - inclusive of patients beginning neoadjuvant or intermittent therapy, being treated locally for advanced disease, or patients beginning therapy for failure of prior local therapy * Patients who have had prior LHRH therapy in an adjuvant or neoadjuvant setting, providing that the last date of effective therapy was greater than 6 months prior to screening * ECOG 0-2 * Morning serum testosterone level \> 150 ng/dL * Standard screening labs within 2x ULN (AST, ALT, bilirubin and serum creatinine) * Hemoglobin \> 10 g/dL * Life expectancy of \>1yr. * Willing to complete both cycles and all procedures of the study Exclusion Criteria: * Any prior (except for prior LHRH therapy in an adjuvant or neoadjuvant setting) or current definitive therapy for prostate cancer, including chemotherapy, immunotherapy, tumor-vaccines,biological response modifiers, or estrogens * Patients who have undergone any prostatic surgery within 4 weeks of Baseline * Patients who have undergone orchiectomy, adrenalectomy, or hypophysectomy * Patients that are currently hospitalized or require frequent hospitalization * Prior resistance to LHRH therapy, either neoadjuvant or adjuvant. * Patients with evidence of spinal cord compression, ureteral obstruction or clinically significant bladder outlet obstruction * Participation in any investigational drug, biologic, or device study within five half-lives of its physiological action or three months prior to enrollment, whichever was longer * Patients anticipated to need concomitant hormonal, anti-androgen, radio-, chemo-, immuno- or surgical therapy for prostate cancer while on study * History of recent drug and/or alcohol abuse within 6 months of screening * History of HIV, HCV or HBV infection * History of hypersensitivity or known allergy to LHRH agonists or antagonists * Concurrent use of daily corticosteroids or other agents known to modify serum androgen within 12 weeks of screening visit * Patients on other anti-androgens such as flutamide, nilutamide or bicalutamide * History of other cancer with the exception of non-metastatic basal or squamous cell carcinoma of the skin * Patients receiving any type of 5-alpha reductase inhibitor such as Proscar, Propecia, or Avodart within the past 3 months * Patients who have experienced a myocardial infarction, unstable or uncontrolled cardiovascular disease or a coronary vascular procedure within 6 months of Baseline * Patients who have experienced venous thrombosis within 6 months of Baseline * Patients with other serious intercurrent illness(es) or disease(s)that might interfere with, or put them at additional risk for, their ability to receive the treatment outlined in the protocol * Patients who have a history of the following: Immunization within 4 weeks of Baseline; Flu shots within 2 weeks of Baseline; Donation or receipt of blood or blood products within 2 months of Baseline; Anaphylaxis * Patients who have received Oakwood's leuprolide acetate formulation previously.